{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T05:11:48Z","timestamp":1737090708891,"version":"3.33.0"},"reference-count":35,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjps"],"DOI":"10.4274\/tjps.galenos.2024.80550","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T12:38:20Z","timestamp":1720442300000},"source":"Crossref","is-referenced-by-count":0,"title":["LACTULOSE VERSUS NALOXONE FOR OPIOID-INDUCED CONSTIPATION IN THE POISONING INTENSIVE CARE UNIT"],"prefix":"10.4274","author":[{"given":"Mitra","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maral","family":"Ramezani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahin","family":"Shadnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Mostafazadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnaz Dahdahsti","family":"Azandaryani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hosein","family":"Alijanzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latif","family":"Gachkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman Erfan Talab","family":"Evini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Bharucha AE, Wald A, editors. Chronic constipation. Mayo Clinic Proceedings; 2019: Elsevier.","DOI":"10.1016\/j.mayocp.2019.01.031"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"141737","DOI":"10.1155\/2014\/141737","article-title":"Opioid-induced constipation: pathophysiology, clinical consequences, and management","volume":"2014","author":"Kumar","year":"2014","unstructured":"2. Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014;2014:141737.","journal-title":"Gastroenterol Res Pract"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008;11:S105-S120.","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.neulet.2003.12.004","article-title":"Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans","volume":"361","author":"Holzer","year":"2004","unstructured":"4. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004;361:192-195.","journal-title":"Neurosci Lett"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Webster LR. Opioid-induced constipation. Pain Med. 2015;16 Suppl 1:S16-S21.","DOI":"10.1111\/pme.12911"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/nmo.12417","article-title":"Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation","volume":"26","author":"Camilleri","year":"2014","unstructured":"6. Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26:1386-1395.","journal-title":"Neurogastroenterol Motil"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ajgsup.2014.7","article-title":"Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach","volume":"2","author":"Dorn","year":"2014","unstructured":"7. Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol Suppl. 2014;2:31-37.","journal-title":"Am J Gastroenterol Suppl"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11S-18S.","DOI":"10.1016\/S0002-9610(01)00782-6"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;2010:CD006605.","DOI":"10.1002\/14651858.CD006605.pub2"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/00325481.2016.1149017","article-title":"Efficacy of methylnaltrexone for the treatment of opioid-induced constipation: a meta-analysis and systematic review","volume":"128","author":"Mehta","year":"2016","unstructured":"10. Mehta N, O'Connell K, Giambrone GP, Baqai A, Diwan S. Efficacy of methylnaltrexone for the treatment of opioid-induced constipation: a meta-analysis and systematic review. Postgrad Med. 2016;128:282-289.","journal-title":"Postgrad Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4137\/CMO.S4867","article-title":"Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide","volume":"5","author":"Bader","year":"2011","unstructured":"11. Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011;5:201-211.","journal-title":"Clin Med Insights Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jpain.2010.11.008","article-title":"Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study","volume":"12","author":"Michna","year":"2011","unstructured":"12. Michna E, Blonsky ER, Schulman S, Yaffe K, Diamond R. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12:554-562.","journal-title":"J Pain"},{"key":"ref12","unstructured":"13. Goodheart CR, Leavitt SB. Managing opioid-induced constipation in ambulatory-care patients. Pain Treat Top. 2006:1-9."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1185\/03007990802584454","article-title":"Fixed-ratio combination oxycodone\/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain","volume":"24","author":"Simpson","year":"2008","unstructured":"14. Simpson K, Leyendecker P, Hopp M, Klose P, Zimmerman B. Fixed-ratio combination oxycodone\/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24:3503-3512.","journal-title":"Curr Med Res Opin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jpain.2008.06.014","article-title":"Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged-release tablets in patients with moderate to severe chronic pain","volume":"9","author":"Vondrackova","year":"2008","unstructured":"15. Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, Ruckes C, Weber S, Grothe B, Fleischer W, Reimer K. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged-release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9:1144-1154.","journal-title":"J Pain"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/01.CCM.0000053652.80849.9F","article-title":"Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia","volume":"31","author":"Meissner","year":"2003","unstructured":"16. Meissner W, Dohrn B, Reinhart K. Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia. Crit Care Med. 2003;31:776-780.","journal-title":"Crit Care Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2710.2008.00982.x","article-title":"Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit","volume":"34","author":"PA","year":"2009","unstructured":"17. Arpino PA, Thompson BT. Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit. J Clin Pharm Ther. 2009;34:171-175.","journal-title":"J Clin Pharm Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jcrc.2014.04.005","article-title":"Enteral naloxone for the treatment of opioid-induced constipation in the medical intensive care unit","volume":"29","author":"CM","year":"2014","unstructured":"18. Gibson CM, Pass SE. Enteral naloxone for the treatment of opioid-induced constipation in the medical intensive care unit. J Crit Care. 2014;29:803-807.","journal-title":"J Crit Care"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/1060028016677310","article-title":"Methylnaltrexone versus naloxone for opioid-induced constipation in the medical intensive care unit","volume":"51","author":"Merchan","year":"2017","unstructured":"19. Merchan C, Altshuler D, Papadopoulos J. Methylnaltrexone versus naloxone for opioid-induced constipation in the medical intensive care unit. Ann Pharmacother. 2017;51:203-208.","journal-title":"Ann Pharmacother"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3344\/kjp.2019.32.2.69","article-title":"Opioid-induced constipation: a narrative review of therapeutic options in clinical management","volume":"32","author":"Lang-Illievich","year":"2019","unstructured":"20. Lang-Illievich K, Bornemann-Cimenti H. Opioid-induced constipation: a narrative review of therapeutic options in clinical management. Korean J Pain. 2019;32:69-78.","journal-title":"Korean J Pain"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s40267-017-0384-z","article-title":"Lactulose: a prebiotic, laxative and detoxifying agent","volume":"33","author":"Pranami","year":"2017","unstructured":"21. Pranami D, Sharma R, Pathak H. Lactulose: a prebiotic, laxative and detoxifying agent. Drugs & Therapy Perspectives. 2017;33:228-233.","journal-title":"Drugs & Therapy Perspectives"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5737\/1181912x234236240","article-title":"Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review","volume":"23","author":"Ruston","year":"2013","unstructured":"22. Ruston T, Hunter K, Cummings G, Lazarescu A. Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review. Can Oncol Nurs J. 2013;23:236-246.","journal-title":"Can Oncol Nurs J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0885-3924(97)00276-5","article-title":"Efficacy of senna versus lactulose in terminal cancer patients treated with opioids","volume":"15","author":"Agra","year":"1998","unstructured":"23. Agra Y, Sacrist\u00e1n A, Gonz\u00e1lez M, Ferrari M, Portugu\u00e9s A, Calvo MJ. Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J Pain Symptom Manage. 1998;15:1-7.","journal-title":"J Pain Symptom Manage"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/j.1552-4604.1997.tb04264.x","article-title":"Tolerance and efficacy of polyethylene glycol 3350\/electrolyte solution versus lactulose in relieving opiate-induced constipation: a double-blinded placebo-controlled trial","volume":"37","author":"Freedman","year":"1997","unstructured":"24. Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350\/electrolyte solution versus lactulose in relieving opiate-induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol. 1997;37:904-907.","journal-title":"J Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0304-3959(99)00185-2","article-title":"Oral naloxone reverses opioid-associated constipation","volume":"84","author":"Meissner","year":"2000","unstructured":"25. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain. 2000;84:105-109.","journal-title":"Pain"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0885-3924(01)00369-4","article-title":"Low-dose oral naloxone reverses opioid-induced constipation and analgesia","volume":"23","author":"Liu","year":"2002","unstructured":"26. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48-53.","journal-title":"J Pain Symptom Manage"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s001010050390","article-title":"Aufhebung einer Morphin-induzierten Obstipation durch orales Naloxon [Treament of morphine-induced constipation with oral naloxone]","volume":"46","author":"Latasch","year":"1997","unstructured":"27. Latasch L, Zimmermann M, Eberhardt B, Jurna I. Aufhebung einer Morphin-induzierten Obstipation durch orales Naloxon [Treament of morphine-induced constipation with oral naloxone]. Anaesthesist. 1997;46:191-194.","journal-title":"Anaesthesist"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.15791","article-title":"Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation","volume":"52","author":"Vijayvargiya","year":"2020","unstructured":"28. Vijayvargiya P, Camilleri M, Vijayvargiya P, Erwin P, Murad MH. Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation. Aliment Pharmacol Ther. 2020;52:37-53.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/0269216311418869","article-title":"A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone\/naloxone prolonged-release tablets in patients with moderate\/severe, chronic cancer pain","volume":"26","author":"Ahmedzai","year":"2012","unstructured":"29. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone\/naloxone prolonged-release tablets in patients with moderate\/severe, chronic cancer pain. Palliat Med. 2012;26:50-60.","journal-title":"Palliat Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1517\/14656560902796798","article-title":"Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomizedrandomized controlled trial","volume":"10","author":"L\u00f6wenstein","year":"2009","unstructured":"30. L\u00f6wenstein O, Leyendecker P, Hopp M, Klose P, Zimmermann G, Wulf H. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomizedrandomized controlled trial. Expert Opin Pharmacother. 2009;10:531-543.","journal-title":"Expert Opin Pharmacother"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/pme.12775","article-title":"New formulation of sustained release naloxone can reverse opioid-induced constipation without compromising the desired opioid effects","volume":"16","author":"Sanders","year":"2015","unstructured":"31. Sanders M, Jones S, L\u00f6wenstein O, Jansen JP, Miles H, Simpson K. New formulation of sustained release naloxone can reverse opioid-induced constipation without compromising the desired opioid effects. Pain Med. 2015;16:1540-1550.","journal-title":"Pain Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejpain.2008.06.012","article-title":"A randomizedrandomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation","volume":"13","author":"Meissner","year":"2009","unstructured":"32. Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K. A randomizedrandomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56-64.","journal-title":"Eur J Pain"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Caraceni A, Hanks G, Kaasa S, Olesen F, Currow D, Lorenz W, De Conno F, Van Der Rijt W. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-e68.","DOI":"10.1016\/S1470-2045(12)70040-2"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW; American Society of Interventional Pain Physicians. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2-guidance. Pain Physician. 2012;15:S67-S116.","DOI":"10.36076\/ppj.2012\/15\/S67"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1111\/pme.12937","article-title":"Consensus recommendations on initiating prescription therapies for opioid-induced constipation","volume":"16","author":"Argoff","year":"2015","unstructured":"35. Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, Gudin J, Lembo A, Stanos SP, Webster LR. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16:2324-2337.","journal-title":"Pain Med"}],"container-title":["Turkish Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T06:38:46Z","timestamp":1737009526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.turkjps.org\/articles\/lactulose-versus-naloxone-for-opioid-induced-constipation-in-the-poisoning-intensive-care-unit\/doi\/tjps.galenos.2024.80550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":35,"URL":"https:\/\/doi.org\/10.4274\/tjps.galenos.2024.80550","relation":{},"ISSN":["1304-530X","2148-6247"],"issn-type":[{"type":"print","value":"1304-530X"},{"type":"electronic","value":"2148-6247"}],"subject":[],"published":{"date-parts":[[2024,7,8]]}}}